Ken Griffin’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-146,932
| Closed | -$15.6M | – | 11089 |
|
|
2020
Q2 | $14.2M | Buy |
146,932
+109,028
| +288% | +$9.09M | 0.01% | 1834 |
|
|
2020
Q1 | $1.78M | Buy |
37,904
+18,254
| +93% | +$1.17M | ﹤0.01% | 4339 |
|
|
2019
Q4 | $1.43M | Sell |
19,650
-23,456
| -54% | -$1.42M | ﹤0.01% | 4955 |
|
|
2019
Q3 | $2.25M | Buy |
43,106
+13,175
| +44% | +$701K | ﹤0.01% | 4295 |
|
|
2019
Q2 | $1.5M | Sell |
29,931
-3,427
| -10% | -$167K | ﹤0.01% | 5016 |
|
|
2019
Q1 | $1.74M | Sell |
33,358
-55,771
| -63% | -$2.57M | ﹤0.01% | 4705 |
|
|
2018
Q4 | $4.36M | Buy |
89,129
+28,167
| +46% | +$1.55M | ﹤0.01% | 2987 |
|
|
2018
Q3 | $3.98M | Sell |
60,962
-90,501
| -60% | -$5.32M | ﹤0.01% | 3306 |
|
|
2018
Q2 | $7.52M | Buy |
151,463
+105,181
| +227% | +$5.09M | ﹤0.01% | 2249 |
|
|
2018
Q1 | $2.26M | Sell |
46,282
-14,393
| -24% | -$748K | ﹤0.01% | 3540 |
|
|
2017
Q4 | $2.55M | Buy |
60,675
+38,636
| +175% | +$1.49M | ﹤0.01% | 3297 |
|
|
2017
Q3 | $944K | Buy |
+22,039
| New | +$703K | ﹤0.01% | 4405 |
|
|
2017
Q1 | – | Sell |
-19,437
| Closed | -$252K | – | 8274 |
|
|
2016
Q4 | $252K | Buy |
+19,437
| New | +$299K | ﹤0.01% | 5927 |
|
Ken Griffin's MYOK Position: Q3 2020 in Review
Ken Griffin sold out of MyoKardia, Inc. Common Stock (MYOK) in Q3 2020, closing a stake of 146,932 shares — an estimated $15.6M sold.
Ken Griffin first reported a position in MYOK in Q4 2016 and held it in 13 quarters. The position peaked at $14.2M in Q2 2020. 237 funds tracked by Wall St. Rank hold MYOK as of Q3 2020.
- Ken Griffin reported no remaining MyoKardia, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
- Ken Griffin sold 146,932 MyoKardia, Inc. Common Stock shares in Q3 2020, an estimated $15.6M.
- Ken Griffin first reported a position in MyoKardia, Inc. Common Stock in Q4 2016 and held it in 13 quarters.
- Ken Griffin's MyoKardia, Inc. Common Stock position peaked at $14.2M in Q2 2020.
- 237 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q3 2020.
Based on Citadel Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.